Enkang Pharmaceutical Overview

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 9

Enkang Pharmaceutical General Information

Description

Developer and manufacturer of therapeutic compounds and delivery systems intended for oncology and respiratory disease treatment. The company offers a novel DNA replication initiation protein (DRIP) inhibition mechanism, proprietary lipid-based inhalation formulations, and nanoparticle encapsulation technologies, serving pharmaceutical and clinical research markets to pursue targeted, low-toxicity therapies with enhanced bioavailability, improved tissue selectivity, and compatibility with international multi-center clinical trial standards.

Contact Information

Website
www.ek-pharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th Floor, Building 4C, Phase II
  • No. 9, Helix 4th Road
  • Guangzhou, Guangdong 510000
  • China
+86 020
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Nanotechnology, Manufacturing, Life Sciences, Oncology
Corporate Office
  • 5th Floor, Building 4C, Phase II
  • No. 9, Helix 4th Road
  • Guangzhou, Guangdong 510000
  • China
+86 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enkang Pharmaceutical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 27-May-2025 Completed Generating Revenue
10. Later Stage VC (Series B2) 03-Dec-2024 Completed Generating Revenue
9. Later Stage VC 13-Nov-2023 Completed Clinical Trials - Phase 3
8. Later Stage VC (Series B) 29-Jan-2023 Completed Clinical Trials - Phase 3
7. Later Stage VC 18-Oct-2022 Completed Clinical Trials - Phase 3
6. Later Stage VC 23-Feb-2022 Completed Clinical Trials - Phase 3
5. Early Stage VC 20-Dec-2021 Completed Startup
4. Early Stage VC 23-Dec-2020 Completed Pre-Clinical Trials
3. Early Stage VC 11-Sep-2019 $11.5M Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Jan-2017 $6.35M $11.5M Completed Pre-Clinical Trials
To view Enkang Pharmaceutical’s complete valuation and funding history, request access »

Enkang Pharmaceutical Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Guangzhou Financial Holdings Corporation Minority
Guangzhou Jinkong Fund Asset Manager Minority
Tianhe Investment Government Minority
Cherami Investment Group Asset Manager Minority
Rastar Group Corporation Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Enkang Pharmaceutical FAQs

  • Where is Enkang Pharmaceutical headquartered?

    Enkang Pharmaceutical is headquartered in Guangzhou, China.

  • What industry is Enkang Pharmaceutical in?

    Enkang Pharmaceutical’s primary industry is Drug Discovery.

  • Is Enkang Pharmaceutical a private or public company?

    Enkang Pharmaceutical is a Private company.

  • What is Enkang Pharmaceutical’s current revenue?

    The current revenue for Enkang Pharmaceutical is .

  • How much funding has Enkang Pharmaceutical raised over time?

    Enkang Pharmaceutical has raised $11.5M.

  • Who are Enkang Pharmaceutical’s investors?

    Guangzhou Financial Holdings, Guangzhou Jinkong Fund, Tianhe Investment, Cherami Investment Group, and Rastar Group are 5 of 9 investors who have invested in Enkang Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process